- ·News
- ·【2017-12-11】Yiling Pharma got the first CMO deal in 2018
- ·【2018-01-03】以岭万洲国际制药——中国制剂出口欧美规范市场的一匹黑马
- ·【2018-01-06】以岭万洲国际制药新药临床样品CMO业务新年取得开门红
- ·【2018-01-16】苏州企业来我公司考察
- ·【2018-01-30】南京企业来我公司质量审计
- ·【2018-01-30】以岭万洲BD人员奔跑在市场第一线
- ·【2018-02-02】泰州企业来我公司考察
- ·【2018-02-06】公司领导参加艾创投系列沙龙
- ·【2018-02-23】2018年以岭医药集团年会
Yiling Pharma got the first CMO deal in 2018 from a client is from South Africa and the drug will be launched in South Africa.
Yiling Pharma has a vertically organized manufacturing infrastructure that is supported by the R&D department and is implemented through Standard Operating Procedures.
Our EU&US GMP-compliant facilities consist of high-end production lines capable of producing pharmaceutical products in a wide range of oral solid dosage forms with 6 billion annual capacity through a range of manufacturing processes as well as corresponding individualized packaging.
Yiling Pharma has been one of the largest CMO manufacturers in China, producing about 900 batches per year, and the products are delivered to USA, UK, Canada, Germany, New Zealand and other markets around the world.
Business Scope
■ Own Drugs Development, Registration and Marketing
■ In/Out Licensing
■ Contract Manufacture:Commercial product
■ Contract Manufacture: Small batches for clinical trial